Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Certolizumab in Crohn's Disease Patients With Loss of Response or Intolerance to Infliximab

ClinicalTrials.gov ID: NCT00308581

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT00308581. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Nov 17, 2026, 6:55 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase IIIb Open-label Induction and Double-blind Comparison of 2 Maintenance Schedules Evaluating Clinical Benefit and Tolerability of Certolizumab Pegol in Crohn's Disease Patients With Prior Loss of Response or Intolerance to Infliximab

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

To assess the clinical efficacy of subcutaneous (sc) certolizumab pegol administration over 26 weeks in patients suffering from Crohn's Disease (CD) and previously treated with infliximab

Study identification

NCT ID
NCT00308581
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
UCB Pharma
Industry
Enrollment
539 participants

Conditions and interventions

Interventions

Biological · Other

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Apr 2006 (Type not available)
Primary completion
Apr 2008 (Actual)
Completion
Apr 2008 (Actual)
Last update posted
Aug 7, 2018

2006 – 2008

United States locations

U.S. sites
31
U.S. states
22
U.S. cities
31
Facility City State ZIP Site status
Not listed San Francisco California — —
Not listed Gainesville Florida — —
Not listed Atlanta Georgia — —
Not listed Chicago Illinois — —
Not listed Indianapolis Indiana — —
Not listed Lexington Kentucky — —
Not listed Louisville Kentucky — —
Not listed Baton Rouge Louisiana — —
Not listed Baltimore Maryland — —
Not listed Boston Massachusetts — —
Not listed Rochester Minnesota — —
Not listed Lincoln Nebraska — —
Not listed Great Neck New York — —
Not listed New York New York — —
Not listed Chapel Hill North Carolina — —
Not listed Charlotte North Carolina — —
Not listed Cincinnati Ohio — —
Not listed Cleveland Ohio — —
Not listed Oklahoma City Oklahoma — —
Not listed Portland Oregon — —
Not listed Philadelphia Pennsylvania — —
Not listed Pittsburgh Pennsylvania — —
Not listed Charleston South Carolina — —
Not listed Germantown Tennessee — —
Not listed Kingsport Tennessee — —
Not listed Nashville Tennessee — —
Not listed Dallas Texas — —
Not listed Galveston Texas — —
Not listed Houston Texas — —
Not listed Seattle Washington — —
Not listed Milwaukee Wisconsin — —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 76 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00308581, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 7, 2018 · Synced Nov 17, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.